Table 3. Characteristics of the patient... | American Society of Hematology

Table 3.

Characteristics of the patient population (case-control study)

Patient Characteristics	Cases^3-150	Controls^3-150
No. patients	22	48
Pretransplant AA score^3-151
Median	200.0	168.5
AA score ≤170	8 (36%)	29 (60%)
AA score >170	14 (64%)	19 (40%)
Pretransplant topoisomerase score
Median	126.5	110.0
Topoisomerase score <110	10 (45%)	26 (54%)
Topoisomerase score >110	12 (55%)	22 (46%)
Pretransplant radiation
Yes (25)	11 (50%)	14 (29%)
No (45)	11 (50%)	34 (71%)
Source of stem cells
BM	4 (18%)	7 (15%)
PSC/BM + PSC	18 (82%)	41 (85%)
Priming with VP-16
No	18 (72%)	45 (94%)
Yes	4 (18%)	3 (6%)
Conditioning regimens
TBI/VP16/CY	16 (73%)	33 (69%)
CBV	6 (27%)	15 (31%)

Patient Characteristics	Cases^3-150	Controls^3-150
No. patients	22	48
Pretransplant AA score^3-151
Median	200.0	168.5
AA score ≤170	8 (36%)	29 (60%)
AA score >170	14 (64%)	19 (40%)
Pretransplant topoisomerase score
Median	126.5	110.0
Topoisomerase score <110	10 (45%)	26 (54%)
Topoisomerase score >110	12 (55%)	22 (46%)
Pretransplant radiation
Yes (25)	11 (50%)	14 (29%)
No (45)	11 (50%)	34 (71%)
Source of stem cells
BM	4 (18%)	7 (15%)
PSC/BM + PSC	18 (82%)	41 (85%)
Priming with VP-16
No	18 (72%)	45 (94%)
Yes	4 (18%)	3 (6%)
Conditioning regimens
TBI/VP16/CY	16 (73%)	33 (69%)
CBV	6 (27%)	15 (31%)

Group-matching criteria included primary disease, age at transplant (±2 y) and duration of follow-up.

AA score is the alkylating agent score.

TBI/VP-16 indicates conditioning with total body irradiation, etoposide, and cytoxan; CBV, conditioning with cytoxan, BCNU, and vincristine.